NVS

Novartis
D

NVS

Arincen80/100B

Novartis operating income 1998–2026

Novartis's operating income in Q3 FY2026, the three months to 30 September 2026, was 1.84B USD, down 59.1% on the same quarter a year before. Novartis's operating income over the last twelve months was 14.33B USD, down 18.4% on the twelve months before. In fiscal year 2025 it was 17.64B USD, up 21.3% on the year before.

Last updated 8 Nov 2026 · Next report 3 Feb 2027

Operating income

Operating income · +7.0% a year over 10 yearsOperating margin

Growth

Fiscal yearPeriod endingOperating incomeGrowthOperating marginGross profitGross marginEBITDA
TTM30 Sept 202614.33B-18.36%25.46%42.02B74.62%21.78B
FY202531 Dec 202517.64B+21.31%32.19%41.12B75.02%22.99B
FY202431 Dec 202414.54B+48.88%28.12%38.90B75.20%20.72B
FY202331 Dec 20239.77B+22.94%20.94%34.19B73.27%18.26B
FY202231 Dec 20227.95B-20.98%18.28%31.88B73.35%14.68B
FY202131 Dec 202110.06B-0.95%22.87%32.24B73.31%30.91B
FY202031 Dec 202010.15B+11.73%20.35%34.78B69.70%17.21B
FY201931 Dec 20199.09B+8.13%18.67%34.25B70.37%15.62B
FY201831 Dec 20188.40B-3.44%18.23%31.59B68.52%20.24B
FY201731 Dec 20178.70B+5.25%20.05%29.77B68.59%14.59B
FY201631 Dec 20168.27B-7.90%16.72%31.92B64.56%14.57B
FY201531 Dec 20158.98B-19.05%17.82%32.98B65.46%14.26B
FY201431 Dec 201411.09B+0.97%20.68%36.29B67.66%17.66B
FY201331 Dec 201310.98B-4.55%20.83%36.14B68.55%15.90B
FY201231 Dec 201211.51B+6.74%22.14%36.11B69.47%16.40B
FY201131 Dec 201110.78B-6.47%18.16%40.39B68.03%17.09B
FY201031 Dec 201011.53B+15.47%22.35%37.07B71.90%15.81B
FY200931 Dec 20099.98B+11.36%22.13%32.92B73.00%12.77B
FY200831 Dec 20088.96B+32.19%21.05%31.15B73.14%12.46B
FY200731 Dec 20076.78B-11.27%17.41%27.92B71.67%10.58B
FY200631 Dec 20067.64B+17.44%21.77%25.69B73.19%10.18B
FY200531 Dec 20056.51B+6.38%21.87%22.31B75.00%8.78B
FY200431 Dec 20046.12B+8.55%22.43%20.58B75.44%7.97B
FY200331 Dec 20035.64B+10.66%22.60%18.47B74.10%7.26B
FY200231 Dec 20025.09B+17.73%24.39%15.88B76.08%7.19B
FY200131 Dec 20014.33B-11.45%23.05%14.02B74.71%5.95B
FY200031 Dec 20004.88B+5.94%22.01%15.84B71.40%5.63B
FY199931 Dec 19994.61B-8.33%22.61%15.17B74.39%5.56B
FY199831 Dec 19985.03B—21.83%15.73B68.29%6.04B

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,EPS,Shares outstanding,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Novartis's operating income

Source: Financial Modeling Prep